Category: Include on Menu
-
On Holding shares drop 5% as CEO Martin Hoffmann announces departure
On Holding AG (NYSE:ONON) shares declined about 5% on Wednesday after the company revealed that Chief Executive Officer Martin Hoffmann will step down after 13 years with the Swiss sportswear company. Starting May 1, company co-founders David Allemann and Caspar Coppetti will take on the roles of Co-CEOs while continuing to serve as Executive Co-Chairmen…
-
Cipher Digital secures 15-year data center lease and $200M revolving credit facility
Cipher Digital Inc. (NASDAQ:CIFR) announced it has signed a 15-year lease agreement for a data center campus with an investment-grade hyperscale tenant and arranged a $200 million revolving credit facility. The agreement represents Cipher’s third contract for a data center campus. As part of the deal, the company will construct and deliver a new high-performance…
-
Honeywell agrees $500 million defense production framework with U.S. government
Honeywell (NASDAQ:HON) said it has entered into a supplier framework agreement with the U.S. Department of War aimed at expanding production of key defense technologies, supported by a $500 million multi-year investment to enhance manufacturing capacity. As part of the agreement, Honeywell Aerospace will boost output of navigation systems, Assure actuators and electronic warfare technologies.…
-
Epsilon tops fourth-quarter forecasts on higher output
Epsilon Energy Ltd. (NASDAQ:EPSN) reported fourth-quarter adjusted earnings per share of $0.43, significantly ahead of analyst expectations of $0.04. Revenue totaled $14.82 million, exceeding the consensus forecast of $11.36 million and marking a 65% increase from $8.98 million in the third quarter. Shares of the company rose about 1.13% in after-hours trading following the announcement.…
-
SSR Mining agrees $1.5 billion sale of Çöpler mine stake to Cengiz Holding
SSR Mining Inc. (NASDAQ:SSRM) has entered into a definitive agreement to sell its 80% interest in the Çöpler mine and associated assets in Turkey to Cengiz Holding A.S. for $1.5 billion in cash. The deal follows a memorandum of understanding between the two companies that was announced in March 2026. Completion of the transaction remains…
-
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period
KalVista Pharmaceuticals Inc. (NASDAQ:KALV) reported global net product revenue of $49.1 million from its therapy EKTERLY during the eight-month period ending December 31, 2025, according to financial results covering the company’s fiscal transition period. Since launch through February, KalVista received 1,702 patient start forms in the United States, representing roughly 20% of the estimated U.S.…
-
Baozun tops Q4 earnings forecasts but shares slip slightly
Baozun Inc. (NASDAQ:BZUN) reported fourth-quarter adjusted earnings of RMB2.75 per ADS ($0.39) on Wednesday, surpassing analyst expectations of RMB1.80. Despite the earnings beat, the company’s shares fell about 1.4% in premarket trading following the release of the results. The brand e-commerce solutions provider generated quarterly revenue of RMB3.17 billion ($453.6 million) for the period ending…
-
Cognyte shares jump more than 7% after earnings beat and strong outlook
Cognyte Software Ltd. (NASDAQ:CGNT) shares rose over 7% in premarket trading Wednesday after the company reported fourth-quarter results that came in ahead of market expectations and issued an optimistic forecast. For the quarter, Cognyte posted adjusted earnings per share of $0.10, exceeding analyst estimates by $0.07. Revenue reached $106.2 million, also beating the consensus forecast…
-
Novo Nordisk and United Laboratories report encouraging phase 2 results for diabetes drug UBT251
Novo Nordisk A/S (NYSE:NVO) and The United Laboratories International Holdings Limited said Wednesday that their jointly developed treatment UBT251 delivered strong improvements in blood glucose control and weight reduction in a phase 2 clinical trial involving Chinese patients with type 2 diabetes. The study evaluated UBT251, a triple agonist designed to activate GLP-1, GIP and…
-
Terns Pharma stock jumps on report of potential $6B takeover by Merck
Terns Pharmaceuticals (NASDAQ:TERN) shares surged in premarket trading after a report indicated that Merck & Company (NYSE:MRK) is close to agreeing a deal to acquire the biotech firm for roughly $6 billion. According to the Financial Times, the proposed all-cash transaction could be finalized within days and would value Terns at a premium to its…